PriceTargets.com logo

Virios Therapeutics - VIRI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 15.38%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.60 As of 11/19/2024 01:00 AM ET
▲ +0.75 (40.54%)

This chart shows the closing price for VIRI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Virios Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIRI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIRI

Analyst Price Target is $3.00
▲ +15.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Virios Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a 15.38% upside from the last price of $2.60.

This chart shows the closing price for VIRI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Virios Therapeutics. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/9/2024HC WainwrightBoost TargetNeutral ➝ Neutral$0.20 ➝ $5.00
8/9/2024HC WainwrightLower TargetNeutral ➝ Neutral$0.40 ➝ $0.20
6/20/2024Maxim GroupInitiated CoverageBuy$1.00
9/20/2022HC WainwrightDowngradeBuy ➝ Neutral
12/15/2021HC WainwrightInitiated CoverageBuy$12.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Virios Therapeutics logo
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $2.60
Low: $1.76
High: $3.03

50 Day Range

MA: $2.48
Low: $0.14
High: $4.99

52 Week Range

Now: $2.60
Low: $0.13
High: $1.04

Volume

637,000 shs

Average Volume

1,049,645 shs

Market Capitalization

$50.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Virios Therapeutics?

The following equities research analysts have issued research reports on Virios Therapeutics in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for VIRI.

What is the current price target for Virios Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Virios Therapeutics in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 15.4%. HC Wainwright has the highest price target set, predicting VIRI will reach $5.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.00 for Virios Therapeutics in the next year.
View the latest price targets for VIRI.

What is the current consensus analyst rating for Virios Therapeutics?

Virios Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VIRI.

What other companies compete with Virios Therapeutics?

Other companies that are similar to Virios Therapeutics include Neurogene, Editas Medicine, Solid Biosciences, XBiotech and Corbus Pharmaceuticals. Learn More about companies similar to Virios Therapeutics.

How do I contact Virios Therapeutics' investor relations team?

The company's listed phone number is 866-620-8655 and its investor relations email address is [email protected]. The official website for Virios Therapeutics is www.virios.com. Learn More about contacing Virios Therapeutics investor relations.